News

Public · Published

Pulmonx Corporation (LUNG) Q3 Revenue $22.8M, +6% YoY; Narrows Loss

Pulmonx reported Q3 2026 revenue of $22.8M, up 6% from a year earlier, with a 76% gross margin. Operating expenses fell 18% and the net loss was $8.4M. The company reaffirmed 2026 revenue guidance of $90–$92M.

Published:

Updated:

What happened

Pulmonx reported Q3 2026 revenue of $22.8M, up 6% from a year earlier, with a 76% gross margin. Operating expenses fell 18% and the net loss was $8.4M. The company reaffirmed 2026 revenue guidance of $90–$92M.

Confirmed

Global impact / market context

Returning to revenue growth while cutting operating expenses by 18% and widening gross margin, which means the share of each sales dollar left after direct costs, points to a turnaround. A smaller net loss of $8.4M reduces cash burn, which means less money spent than earned, and extends how long the company can fund itself.

Analyst inference

The article calls this an early sign of stabilization after prior declines, with a China distributor restart still pending. Cost cuts and better profit per sale support the turnaround story, but the reaffirmed guidance suggests management is not yet counting on a strong rebound in that market.

Analyst inference

What to watch

  1. Pulmonx reaffirmed its 2026 revenue outlook of $90–$92M and now expects a gross margin of about 77% with operating expenses of $108–$109M. Confirmed
  2. Watch whether the China distributor restart, which is a resumption of sales through a local partner, gains pace and lifts growth toward double digits as the article suggests. Proposed
  3. Track whether lower operating expenses and expanding gross margin keep shrinking the net loss, since further narrowing would reduce cash burn and strengthen the path to breakeven. Analyst inference

Evidence